Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Novartis's acquisition of Kate Therapeutics gives it a pipeline of gene therapies for three genetic neuromuscular diseases.

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

Regenxbio hopes to use the study's results to ask the U.S. Food and Drug Administration to grant accelerated approval to the ...

Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00.Don't ...

Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...

In recent weeks, global markets have experienced a degree of volatility, with U.S. stocks giving back some gains amid uncertainties surrounding the incoming Trump administration's policies and their ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

周二，Piper Sandler维持对Sarepta Therapeutics (NASDAQ:SRPT)股票的增持评级，目标价保持在$200.00。该公司的立场是在竞争对手RGNX披露其用于杜氏肌营养不良症(DMD)的基因疗法RGX-202的最新进展之后做出的，该疗法正在进入关键性试验阶段。 更新内容包括研究第1/2阶段首五名患者的初步功能数据，显示功能改善和良好的安全性，未报告严重不良事件(S ...

Key trial endpoints include the proportion of patients with significant microdystrophin expression at week 12, as well as ...